Skip to Content

Emerging Markets Panel

“Assessing Risks/Returns as Healthcare Companies and Investors Seek Opportunities in Developing Markets”

ISSUES

 

  • Current opportunities & barriers/risks for global healthcare companies investing in, and marketing to, emerging markets (China, India, Brazil, Russia, Turkey, others).
  • Trends and examples of innovative cross-border deals in these regions, including R&D collaborations.    
  • What global healthcare companies can learn from local medical innovation.
  • How health reform initiatives in emerging markets (e.g., China) are impacting the healthcare dynamics in these markets (payors, providers, manufacturers).
  • Key success factors in making public-private partnerships work in addressing global health issues in developing countries.  
  • How will the emerging market healthcare landscape shape-up in the next 3-5 years?

 

Rachel Zhang
Principal
McKinsey & Co.

Rachel Zhang is a Partner in McKinsey & Company’s New York Office.   Ms. Zhang focuses on the healthcare industry and worked extensively with leading global pharmaceutical companies across strategy, operations, and organization topics including global innovation, emerging market growth, and global leadership development.  In addition, she also serves clients in global health sector including The Bill and Melinda Gates Foundation. 

Prior to joining McKinsey, Ms. Zhang worked as a biochemist for Merck Research Laboratories in West Point, PA, before obtaining MBA in Strategic Management from The Wharton School.  Ms. Zhang is a member of the BayHelix Group, which connects leaders of Chinese heritage in the global life science and healthcare community.  She was born and grew up in Shanghai, China.

Kevin Ali
President, Emerging Markets
Merck & Co., Inc.

Kevin Ali is responsible for Merck's Emerging Markets Region, and is a member of the company's Global Human Health Operating Committee. The Emerging Markets business is expected to account for 25% of Merck's pharmaceutical and vaccine revenue by 2013.

Kevin previously led Merck's BRID franchise, which encompasses products in the bone, respiratory, immunology, and dermatology disease areas worldwide. He has held a number of marketing and business roles in Europe, North America, and the Middle East including those of Managing Director, Germany, and Managing Director, Turkey.

Mr. Ali joined Merck in 1988, as a Senior Hospital Sales Representative in California. He holds a Bachelor of Arts in Development Studies from the University of California at Berkeley, and an MBA from Santa Clara University. Kevin and his wife Hanaa have two children.

Nanette Cocero PhD
VicePresident, Commercial Specialty/Oncology, Emerging Markets
Pfizer Inc.

Nanette Cocero was appointed Vice President, Specialty Care & Oncology Commercial Unit, Emerging Markets Business Unit, in July 2011. Nanette’s previous role was Head of Specialty Care, Pfizer Spain and she had been in that role since January 2009 when the role was established with the formation of the business units model. Nanette´s significant contributions in this role include successfully leading the establishment of the Specialty Care Business Unit in Spain, including integrating Wyeth colleagues and assets into the Spanish Specialty Care organization while maintaining a highly engaged and effective team focused on understanding and meeting customer needs.

Prior to this role, Nanette was the Marketing Director for Pfizer Spain since 2007. She joined Pfizer in 2002 and was named Regional Marketing Director, Latin America in 2003, and there after held positions of increasing responsibility. Prior to joining Pfizer, Nanette worked in the management consulting industry, specializing in pharma and biotechnology. Nanette earned a Bachelor of Science degree in chemistry from Cornell University; a Ph.D. in pharmacology from the University of Pennsylvania, and an MBA from The Wharton Business School.

Hervé Hoppenot
President
Novartis Oncology

Hervé Hoppenot is President of Novartis Oncology, where he leads the global Oncology business unit, the largest franchise in Novartis, ranking second in the global Oncology segment and supported by more than 6,000 employees in 50 countries. Novartis Oncology markets seven key products - Afinitor, Glivec, Femara, Zometa, Sandostatin LAR, Exjade and Tasigna - and has a leading pipeline in the industry. In 2010, net sales for Novartis Oncology grew 11% in local currencies to $10 billion.

Prior to his role as President, Hervé served as Chief Commercial Officer and Head of Global Product Strategy & Scientific Development, overseeing Medical Affairs, Global Brand Leadership, Business Development and Licensing, Health Economics & Pricing, Early Phase Commercial Development, Strategic Capabilities and Global Sales Excellence for Novartis Oncology. Hervé joined Novartis in 2003 as Senior Vice President, Head of Global Marketing.

Before joining Novartis, Hervé served as Vice President of Oncology for Aventis where he led the Oncology Business Unit in the U.S.

Hervé started his career in the corporate finance audit department of Rhone Poulenc (RP). In 1987 he joined the sales and marketing team of Laboratoire Roger Bellon, one of RP’s French affiliates and in 1989, he was named the company’s international product manager for Oncology and AIDS. After moving to the U.S. organization in 1991 and holding various sales and marketing positions, Hervé was named Vice President for Rhone Poulenc Rorer’s U.S. Oncology operations. RPR became Aventis in 2000.

Alex Preker MD PhD
Head Health Industry & Investment Policy
The World Bank

Mr. Preker is Head of the Health Industry Group and Health Investment Policy Analysis for the Investment Climate Department of the World Bank Group. He leads a team of advisors and analysts that work with policy makers, investors and health businesses in improving the market environment for private sector participation in the health sector in developing countries. Mr. Preker has worked at the World Bank, International Finance Corporation (IFC) and World Health Organization (WHO). Previously, as Chief Economist for the health sector, he coordinated the technical team that prepared the World Bank’s Health, Nutrition and Population Sector Strategy in 1997. He has written many scientific articles and is the author of over 15 books.

Mr. Preker is Adjunct Professor of Health Policy and Management in the Mailman School at Columbia University and Adjunct Professor of Public Administration and Health at the Wagner Graduate School of Public Service at NYU. He has teaching appointments at the Berkeley/Cambridge Health Leadership Forum and McGill University in Montreal. He is on the External Advisory Board for the London School of Economics and Political Science, Health Group. He holds a Ph.D. in Economics from the London School of Economics and Political Science, a Fellowship in Medicine from University College London, a Diploma in Medical Law and Ethics from King’s College London, and a MD from University of British Columbia/McGill.